Journal of Internal Medicine Concepts & Practice >
Research progress of interleukin⁃37 effect on cardiovascular diseases
SU Zhengjia, XIANG Xiaogang, LIANG Qiuli, et al . Research progress of interleukin⁃37 effect on cardiovascular diseases[J]. Journal of Internal Medicine Concepts & Practice, 2023 , 18(03) : 221 -224 . DOI: 10.16138/j.1673-6087.2023.03.018
| [1] | Rafiei A, Ahmadi R, Kazemian S, et al. Serum levels of IL-37 and correlation with inflammatory cytokines and clinical outcomes in patients with coronary artery disease[J]. J Investig Med, 2022, 70(8): 1720-1727. |
| [2] | Jia C, Zhuge Y, Zhang S, et al. IL-37b alleviates endothelial cell apoptosis and inflammation in Kawasaki disease through IL-1R8 pathway[J]. Cell Death Dis, 2021, 12(6): 575. |
| [3] | Nold-Petry CA, Nold MF. Rationale for IL-37 as a novel therapeutic agent in inflammation[J]. Expert Rev Clin Immunol, 2022, 18(12): 1203-1206. |
| [4] | Qin YF, Ren SH, Shao B, et al. The intellectual base and research fronts of IL-37: a bibliometric review of the literature from WoSCC[J]. Front Immunol, 2022, 13: 931783. |
| [5] | Yang Z, Kang L, Wang Y, et al. Role of IL-37 in cardiovascular disease inflammation[J]. Can J Cardiol, 2019, 35(7): 923-930. |
| [6] | Su Z, Tao X. Current understanding of IL-37 in human health and disease[J]. Front Immunol, 2021, 12: 696605. |
| [7] | Zhuang X, Wu B, Li J, et al. The emerging role of interleukin-37 in cardiovascular diseases[J]. Immun Inflamm Dis, 2017, 5(3): 373-379. |
| [8] | Lotfy H, Moaaz M, Moaaz M. The novel role of IL-37 to enhance the anti-inflammatory response of regulatory T cells in patients with peripheral atherosclerosis[J]. Vascular, 2020, 28(5): 629-642. |
| [9] | 陈少源, 方红城, 黄于朗, 等. 白细胞介素37/Smad3在兔腹主动脉粥样硬化斑块中的表达研究[J]. 中国心血管杂志, 2019, 24(2): 161-165. |
| [10] | 朱静和, 钱雷, 蒋凤, 等. 白细胞介素37对动脉粥样硬化患者单核巨噬细胞脂蛋白相关磷脂酶A2的抑制作用[J]. 中华老年心脑血管病杂志, 2020, 22(8): 873-875. |
| [11] | Liu J, Lin J, He S, et al. Transgenic overexpression of IL-37 protects against atherosclerosis and strengthens plaque stability[J]. Cell Physiol Biochem, 2018, 45(3): 1034-1050. |
| [12] | Liu K, Tang Q, Zhu X, et al. IL-37 increased in patients with acute coronary syndrome and associated with a worse clinical outcome after ST-segment elevation acute myocardial infarction[J]. Clin Chim Acta, 2017, 468: 140-144. |
| [13] | Liu C, Cui Y, Zhang D, et al. Analysis of serum interleukin-37 level and prognosis in patients with ACS[J]. Comput Math Methods Med, 2021, 2021:3755458. |
| [14] | McCurdy S, Yap J, Irei J, et al. IL-37-a putative therapeutic agent in cardiovascular diseases[J]. QJM, 2022, 115(11): 719-725. |
| [15] | Yang T, Fang F, Chen Y, et al. Elevated plasma interleukin-37 playing an important role in acute coronary syndrome through suppression of ROCK activation[J]. Oncotarget, 2017, 8(6): 9686-9695. |
| [16] | Li X, Hu H, Guo D, et al. Imbalance of pro- and anti-inflammatory cytokines induced different types of recurrent atrial arrhythmias after drug eluting coronary stent implantation[J]. Curr Vasc Pharmacol, 2022, 20(5): 447-456. |
| [17] | Mao X, Zhu R, Zhang F, et al. IL-37 plays a beneficial role in patients with acute coronary syndrome[J]. Mediators Inflamm, 2019, 2019: 9515346. |
| [18] | Zhu R, Zhang F, Pan C, et al. Role of IL-37- and IL-37-treated dendritic cells in acute coronary syndrome[J]. Oxid Med Cell Longev, 2021, 2021: 6454177. |
| [19] | Shou X, Lin J, Xie C, et al. Plasma IL-37 elevated in patients with chronic heart failure and predicted major adverse cardiac events[J]. Dis Markers, 2017, 2017: 9134079. |
| [20] | 曲延成, 杨赞. 慢性心力衰竭患者心功能与血浆IL-18、IL-37及IL-33的相关性研究[J]. 贵州医药, 2018, 42(6): 659-661. |
| [21] | 王毅, 陈海潮, 林静, 等. 慢性心力衰竭患者血浆白介素-37水平变化研究[J]. 临床医学研究与实践, 2019, 4(5): 93-95. |
| [22] | de Sanctis JB. Innate immune response in hypertension[J]. Curr Pharm Des, 2022, 28(36): 2984-2990. |
| [23] | Ye J, Wang Y, Wang Z, et al. Circulating IL-37 levels are elevated in patients with hypertension[J]. Exp Ther Med, 2021, 21(6): 558. |
| [24] | 胡耀明, 雷慧娟. IL-6、IL-18与心房颤动的关系研究[J]. 实用中西医结合临床, 2019, 19(8): 1-2. |
| [25] | Li W, Li S, Li X, et al. Interleukin-37 elevation in patients with atrial fibrillation[J]. Clin Cardiol, 2017, 40(2): 66-72. |
| [26] | Li J, Zhang WJ, Yao H, et al. Therapeutic effects of interleukin-37 and induced cardiosphere on treating myocardial ischemia-reperfusion injury[J]. Int Immunopharmacol, 2020, 88:106719. |
| [27] | Wang YM, Zhang JJ, Wu BW, et al. IL-37 improves mice myocardial infarction via inhibiting YAP-NLRP3 signaling mediated macrophage programming[J]. Eur J Pharmacol, 2022, 934:175293. |
| [28] | López-Bautista F, Posadas-Sánchez R, Vázquez-Vázquez C, et al. IL-37 gene and cholesterol metabolism: association of polymorphisms with the presence of hypercholesterolemia and cardiovascular risk factors[J]. Biomolecules, 2020, 10(10): 1409. |
| [29] | López-Bautista F, Posadas-Sánchez R, Vargas-Alarcón G. Association of the IL-37 polymorphisms with transaminases and alkaline phosphatase levels in premature coronary artery disease patients and healthy controls[J]. Diagnostics (Basel), 2021, 11(6): 1018. |
| [30] | Yin D, Naji DH, Xia Y, et al. Genomic variant in IL-37 confers a significant risk of coronary artery disease[J]. Sci Rep, 2017, 7: 42175. |
/
| 〈 |
|
〉 |
